Literature DB >> 11270397

Identification and expression of multidrug resistance-related ABC transporter genes in Candida krusei.

S K Katiyar1, T D Edlind.   

Abstract

Infections with Candida krusei have increased in recent years as a consequence of its intrinsic resistance to fluconazole, an antifungal azole widely used in immunocompromised individuals to suppress infections due to azole-susceptible C. albicans. One established mechanism for azole resistance is drug efflux by ATP binding cassette (ABC) transporters. Since these transporters recognize structurally diverse drugs, their overexpression can lead to multidrug resistance (MDR). To identify C. krusei genes potentially involved in azole resistance, PCR was performed with primers corresponding to conserved sequences of MDR-related ABC transporters from other fungi. Two genes, ABC1 and ABC2, were identified; Southern blots suggested that both have one or two related gene copies in the C. krusei genome. ABC1 RNA was constitutively expressed at low levels in log phase cells while ABC2 RNA was undetectable. However, both genes were upregulated as cultures approached stationary phase, and this upregulation was correlated with decreased susceptibility to the lethal activity of the azole derivative miconazole. Furthermore, ABC1 was upregulated following brief treatment of C. krusei with miconazole and clotrimazole (but not other azoles), and the unrelated compounds albendazole and cycloheximide. The latter two compounds antagonized fluconazole activity versus C. krusei, supporting a role for the ABC1 transporter in azole efflux. Finally, miconazole-resistant mutants selected in vitro demonstrated increased constitutive expression of ABC1. Based on these expression data, genetic and functional characterization of the ABC1 transporter to directly test its role in C. krusei azole resistance would appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11270397     DOI: 10.1080/mmy.39.1.109.116

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  32 in total

1.  Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; M A Pfaller; B Bustamante; E Canton; A Fothergill; J Fuller; G M Gonzalez; C Lass-Flörl; S R Lockhart; E Martin-Mazuelos; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M W Szeszs; G St-Germain; L X Bonfietti; J Guarro; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

2.  The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.

Authors:  Ann R Holmes; Mikhail V Keniya; Irena Ivnitski-Steele; Brian C Monk; Erwin Lamping; Larry A Sklar; Richard D Cannon
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

3.  In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.

Authors:  Elisabete Ricardo; Isabel M Miranda; Isabel Faria-Ramos; Raquel M Silva; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Mechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration.

Authors:  Elisabete Ricardo; Fréderic Grenouillet; Isabel M Miranda; Raquel M Silva; Guilluame Eglin; Nadège Devillard; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

5.  Antifungal activity of baicalein against Candida krusei does not involve apoptosis.

Authors:  Kai Kang; Wing-Ping Fong; Paul Wai-Kei Tsang
Journal:  Mycopathologia       Date:  2010-07-08       Impact factor: 2.574

6.  Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.

Authors:  W Lamar Smith; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 7.  Fungal infections in animals: a patchwork of different situations.

Authors:  Seyedmojtaba Seyedmousavi; Sandra de M G Bosco; Sybren de Hoog; Frank Ebel; Daniel Elad; Renata R Gomes; Ilse D Jacobsen; Henrik Elvang Jensen; An Martel; Bernard Mignon; Frank Pasmans; Elena Piecková; Anderson Messias Rodrigues; Karuna Singh; Vania A Vicente; Gudrun Wibbelt; Nathan P Wiederhold; Jacques Guillot
Journal:  Med Mycol       Date:  2018-04-01       Impact factor: 4.076

8.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Cyclic AMP signaling pathway modulates susceptibility of candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors.

Authors:  Pooja Jain; Indira Akula; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Fungal PDR transporters: Phylogeny, topology, motifs and function.

Authors:  Erwin Lamping; Philippe V Baret; Ann R Holmes; Brian C Monk; Andre Goffeau; Richard D Cannon
Journal:  Fungal Genet Biol       Date:  2009-10-24       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.